Sign In
Buy CAPR
$3.85
-0.240 (-5.87%)
At Close: Aug 10, 2026
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
01:17pm, Monday, 27'th Jul 2026
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Monday.
Capricor Therapeutics investors should submit their transactions to Block & Leviton for a complimentary case review amid securities fraud investigation.
QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli
12:02pm, Monday, 27'th Jul 2026
‘Pharma Bro' Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a consultant over patient data.
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
11:00am, Monday, 27'th Jul 2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provid
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy
10:52am, Monday, 27'th Jul 2026
Capricor Therapeutics (NASDAQ:CAPR) shares fell about 67% on Monday after US Food and Drug Administration (FDA) staff reviewers raised concerns about the evidence supporting the effectiveness of the c
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
09:19am, Monday, 27'th Jul 2026
Shares of Capricor Therapeutics Inc. (NASDAQ:CAPR) dropped more than 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.
FDA staff flags concerns for Capricor's Duchenne heart disease therapy
08:27am, Monday, 27'th Jul 2026
U.S. Food and Drug Administration staff reviewers raised concerns about whether Capricor Therapeutics' cell therapy deramiocel has sufficient evidence of effectiveness for t
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy
06:50am, Monday, 27'th Jul 2026
Capricor Therapeutics (NASDAQ:CAPR) shares fell about 67% on Monday after US Food and Drug Administration (FDA) staff reviewers raised concerns about the...
Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR)
02:02am, Sunday, 26'th Jul 2026
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors acquired 12,356 call options on the stock. This is an incre
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
07:11am, Saturday, 25'th Jul 2026
Karen Krasney, EVP, General Counsel, sold 24,100 common shares for a transaction value of ~$732,000 on June 25, 2026, at a weighted average price of around $30.38 per share. The transaction was execut
What's Going On With Capricor Therapeutics Stock On Friday?
02:06pm, Friday, 26'th Jun 2026
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
Caprock Announces Closing of Private Placement
05:47pm, Friday, 19'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered pri
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
04:32pm, Wednesday, 17'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mi
